Beta-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice-Reference-Cited by-同舟云学术

Beta-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice

Published:2005-10 Issue:1-3 Volume:521 Page:164-168
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Ahrén Bo,Sörhede Winzell Maria,Burkey Bryan,Hughes Thomas E.

Publisher

Elsevier BV

Subject

Pharmacology

Reference34 articles.

1. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet derived progenitor cells into insulin-producing cells;Abraham;Endocrinology,2002

2. Insulinotropic action of truncated glucagon-like peptide-1 in mice;Ahrén;Acta Physiol. Scand.,1995

3. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice;Ahrén;Am. J. Physiol.,1999

4. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice;Ahrén;Eur. J. Pharmacol.,2000

5. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes;Ahrén;Diabetes Care,2002

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dipeptidyl Peptidase-4 Inhibitory Activity of Indonesian Anti-Diabetic Herbs: Carica papaya, Tithonia diversifolia, Urena lobata;Research Journal of Pharmacy and Technology;2023-01-27

2. The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review;Gynecological Endocrinology;2019-12-20

3. Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2;Cancer Letters;2018-04

4. Sex and gender influences on pharmacological response: an overview;Expert Review of Clinical Pharmacology;2014-05-24

5. Mody-3: Novel HNF1A Mutation and the Utility of Glucagon-Like Peptide (GLP)-1 Receptor Agonist Therapy;Endocrine Practice;2014-02